- Home
- RSF vs BCAB Comparison
RSF vs BCAB Comparison
Compare RSF & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | BCAB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RSF | BCAB |
|---|---|---|
| Price | $14.41 | $0.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 11.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.81 | $0.24 |
| 52 Week High | $16.23 | $1.43 |
Technical Indicators
Market Signals| Indicator | RSF | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 45.49 |
| Support Level | $14.40 | $0.74 |
| Resistance Level | $14.65 | $0.83 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.05 | 9.86 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.